Combination of Revvity’s proprietary Pin-point platform and Profluent’s AI-engineered proteins created to inspire accelerated development of novel gene editing therapies This new Pin-point ...
Precision DNA editing targets root cause of severe childhood epilepsy in a preclinical study. Researchers from The Jackson Laboratory (JAX; ME, USA) have used gene ...
New research demonstrates the potential of precise genome editing technologies, called adenine base editors, to correct disease-causing mutations in stem cells from patients with X-linked chronic ...
A collaborative effort between investigators at the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) and Massachusetts General Hospital (MGH), a founding ...
New gene editing techniques, like adenine base editing and prime editing, are creating new possibilities for treating dilated cardiomyopathy, a heart condition affecting about 1 in 250 people ...
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) announced a strategic collaboration with Profluent, bringing together a range of its novel AI-engineered enzymes with Revvity’s established ...
A collaborative effort between investigators at the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) and Massachusetts General Hospital (MGH) demonstrates ...
(RTTNews) - Revvity, Inc. (RVTY) announced a strategic collaboration with Profluent, resulting in a simplified access for customers to a therapeutically relevant base editing toolkit. The new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results